Published in final edited form as:

J Mol Biol. 2011 August 12; 411(2): 329–333. doi:10.1016/j.jmb.2011.05.046.

Conserved C-terminal Charge Exerts a Profound Influence on the Aggregation Rate of α -Synuclein

Katerina Levitan¹, David Chereau², Samuel I. A. Cohen³, Tuomas P. J. Knowles³, Christopher M. Dobson³, Anthony L. Fink¹, John P. Anderson², Jason M. Goldstein², and Glenn L. Millhauser^{1,*}

¹ Department of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064

² Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080

³ Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW UK

Abstract

α -synuclein is the major component of filamentous Lewy bodies found in the brains of patients diagnosed with Parkinson's disease. Recent studies demonstrate that, in addition to the wild-type sequence, α -synuclein is found in several modified forms, including truncated and phosphorylated species. Although the mechanism by which the neuronal loss in Parkinson's disease occurs is unknown, aggregation and fibril formation of α -synuclein is considered to be a key pathological feature. In this study we analyze the rates of fibril formation and the monomer-fibril equilibrium for eight disease-associated truncated and phosphorylated α -synuclein variants. Comparison of the relative rates of aggregation reveals a strong monotonic relationship between the C-terminal charge of α -synuclein and the lag time prior to the observation of fibril formation, with truncated species exhibiting the fastest aggregation rates. Moreover, we find that a decrease in C-terminal charge shifts the equilibrium to favor the fibrillar species. An analysis of these findings in the context of linear growth theories suggests that the loss of the charge-mediated stabilization of the soluble state is responsible for the enhanced aggregation rate and increased extent of fibril fraction. Therefore, C-terminal charge is kinetically and thermodynamically protective against α -synuclein polymerization and may provide a target for the treatment of Parkinson's Disease.

Parkinson's disease (PD) is a neurodegenerative disorder associated with the loss of dopaminergic neurons in the substantia nigra of the brain. A primary pathological feature of Parkinson's disease is the presence of Lewy bodies (LBs), which are cellular inclusions composed largely of aggregates of the protein α -synuclein (α -syn)¹ in the form of amyloid fibrils.² In addition to wild-type α -syn, LBs also contain α -syn variants, including phosphorylated, ubiquitinated, acylated and truncated forms of the protein.^{3; 4} It has been shown, for example, that 15% of α -syn found in LBs is C-terminally truncated and 90% is phosphorylated.^{5; 6} Although these variants exhibit significant differences in their tendencies to aggregate and disrupt cellular processes, the kinases and proteases responsible for phosphorylation and truncation, respectively, have not been clearly identified.⁷

© 2011 Elsevier Ltd. All rights reserved.

*Address correspondence to: G. Millhauser, glennm@ucsc.edu; voice: 831 459 2176.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The 140-amino-acid α -syn protein (Table 1) is natively unfolded in solution, but its N-terminus (residues 1-100) adopts an α -helical conformation upon interaction with membranes.^{8; 9; 10} The central region (residues 30-95), including the hydrophobic NAC sequence,¹¹ is involved in the formation of cross β -sheet structure in LB amyloid fibrils.¹² The net charge of the full-length α -syn is -9 , arising largely from the high density of acidic amino acids in the disordered C-terminal region (residues 96-140, Table 1). Previous work suggests that this highly charged C-terminal domain exerts an influence on the aggregation kinetics of α -syn.^{13; 14} With regard to phosphorylation, which also alters polypeptide charge, there is considerable interest in the variant modified at Ser129, an abundant species in PD lesions.¹⁵ In this study, we report experiments involving an array of the natural α -syn variants found in Lewy bodies, including the dominant truncated and phosphorylated species. We find qualitatively, in accord with previous studies,^{13; 14} that C-terminal charge and phosphorylation influence the kinetics of aggregation. By combining quantitative data from all species, however, we uncover a remarkable, monotonic relationship between α -syn charge and the lag time (τ_{lag}) associated with polymerization (fig 1).

The following α -syn species were used in the study: full-length wild-type α -syn (WT); α -syns with C-terminal truncation at residues 135 (D135), 133 (Y133), 122 (N122) and 119 (D119); Ser129-phosphorylated full-length α -syn (P-syn), and Ser129-phosphorylated truncates (P-Y133) and (P-D135) (Table 1). The kinetics of fibril formation were monitored by Thioflavin T fluorescence (Supplemental Information). All the experiments were conducted at pH 7.4, in 20 mM phosphate and 100 mM NaCl; lag times prior to the observation of fibril growth were extracted from an average of 4 trials. By comparing lag times of different modifications we observe two main features. First, the phosphorylated α -syns, including both full-length and truncated species, form fibrils more slowly than their non-phosphorylated counterparts; these data support a previous finding that phosphorylation of α -syn at Ser-129 inhibits fibril formation.¹⁶ Second, the truncated species form fibrils significantly faster than the full-length wild-type α -syn, with shorter sequences resulting in shorter lag times.

In order to explore a more global relationship among these factors, lag times were evaluated as a function of charge to compare the relative rates among all modified α -syns (Figure 1a). The C-terminal charge on residues 91-140 for each modified α -syn (Table 1) was calculated using full-length wild type α -syn (charge = -12) as a reference state. Larger truncations remove more of the acidic amino acids, resulting in a lower negative charge. Phosphorylation, on the other hand, increases the negative charge on the protein, as at pH 7.4 two of the three oxygens on the phosphate group are deprotonated, thus contributing an additional charge of -2 to the C-terminus.

Figure 1a shows that the observed lag times exhibit a monotonic dependence on α -syn C-terminal charge, with more negative species aggregating more slowly.¹⁷ The lag times range over more than an order of magnitude, clearly emphasizing the importance of the C-terminal charge of α -syn in regulating the rate of aggregation. Phosphorylation modifies charge, but without affecting polypeptide length, demonstrating that length alone cannot account for the relationship seen in Figure 1a.

In addition to examining the lag times prior to fibril formation, we also quantified the fraction of fibrillar material at the end of the aggregation reaction (Supplemental Information). For each α -syn variant, fibrillar and non-fibrillar species were separated by centrifugation into insoluble and soluble fractions, respectively. The α -syn concentration in the soluble fraction was determined by UV absorbance at 280 nm. In addition, each sample was evaluated by dynamic light scattering, which revealed a dominant species ($>90\%$) with a radius of gyration consistent with monomeric α -syn (2.1 – 2.9 nm). Subtraction of the

monomer concentration from total peptide concentration at the beginning of a trial gave the percent fibril. As a final check, UV absorbance measurements performed directly on resuspended fibrils agreed with the more rigorous assay based on monomer to within 10%.¹⁸ Our results, shown in Figure 1b, demonstrate that the equilibrium between dissociated and aggregated protein is strongly influenced by C-terminal charge in a systematic manner, with more negative species possessing an increased tendency to remain in their soluble states.

The physiological significance of negative charge in the C-terminal region was further investigated with a sequence alignment of α -syn orthologs from 15 different mammals. The results show an almost perfect conservation of acidic residues, and complete conservation of Ser129, in the C-terminal region (Figure 2), and suggest that α -syns have evolved to adopt a state that is relatively resistant to aggregation, and that reduction of this protective feature in α -syn truncates could play a role in PD pathology.

Post-translational modifications are implicated in many proteins associated with neurodegenerative disorders. For example, N-terminal truncations of the A β peptide, found in Alzheimer's plaques, enhance aggregation and neurotoxicity;^{19; 20} the hydrophilic N-terminal domain of A β flanks the β -core region and is thought to promote fibril formation by aiding protofilament packing into the fibril structure.¹⁹ Along with our studies, it appears that domains adjacent to an amyloidogenic core can remotely regulate aggregation, and thus might play a key role in modulating the development of neurodegenerative disorders.

Amyloid formation is characterized by several microscopic rate constants describing fibril elongation (k_+), fibril depolymerization (k_{off}) and the dominant nucleation mechanism (k_N) which can take the form of primary nucleation,²¹ monomer-dependent secondary nucleation²² or fragmentation.²³ All of these processes can contribute to the timescale of the observed lag phase. For instance, it is clear that an increase in the monomer addition rate k_+ reduces the time taken for a threshold amount of monomer to be incorporated into aggregates. In order to determine which microscopic process is primarily affected by the change in C-terminal charge, we considered quantitatively the effect on the lag time and the fibril fraction (χ) after the reaction has come to completion following the lag phase, when we vary each of the rate constants individually, while holding the other rate constants fixed. Based on a previous analysis,²⁴ we note first that if the dominant nucleation rate, k_N , is increased while holding all of other rates constant, the lag time would decrease, while the final fibril fraction would remain approximately constant (see Supplemental Information), which is inconsistent with the significant changes in fibril fraction observed in our data (Figure 3). However, an increase in either the rate of monomer addition to fibrils (elongation), k_+ , or monomer dissociation from fibrils (depolymerization), k_{off} , would result in the observed trend (Figure 3) of a concurrent increase in fibril fraction χ and decrease in lag time t_{lag} , but with different functional forms (see Supplemental Information):

$$\tau_{\text{lag}} \propto \sqrt{\frac{1}{\chi}} \quad k_{\text{off}} \text{ varied; } k_N, k_+ \text{ constant} \quad (1)$$

$$\tau_{\text{lag}} \propto \sqrt{\frac{1-\chi}{\chi}} \quad k_+ \text{ varied; } k_N, k_{\text{off}} \text{ constant} \quad (2)$$

We systematically compared the predictions of equations (1) and (2) to the experimental data (Figure 3). While both equations (1) and (2) give a decrease in lag time with an increase in fibril fraction, the case where k_{off} is affected results in a dependence that is too weak to

capture the trend in our data. In contrast, variation of the fibril elongation rate k_+ is able to capture quantitatively the significant decrease in lag time with fibril fraction observed in our measurements. From a qualitative perspective, the different dependencies of equations (1) and (2) originate from the fact that the depolymerisation rate k_{off} and the elongation rate k_+ both affect the fibril fraction with an equal weighting, whereas the net fibril growth, as reflected in reduced τ_{lag} , is controlled primarily through the elongation rate.

Previous studies suggest that both electrostatic and hydrophobic long-range interactions, between the acidic C-terminal domain of α -syn and the remainder of the protein, tend to inhibit aggregation.²⁵ Spin label NMR experiments using paramagnetic relaxation enhancement to extract long-range distances identify contacts between the hydrophobic NAC region and the acidic C-terminus.^{26; 27} As proposed in these studies, hydrophobic segments in the C-terminal tail may interact with the NAC region, while the high density of negative charges serve to maintain solubility. In this scenario, both charge conservation and separation between the charges, maintained by specific hydrophobic segments, are important and explain the near perfect sequence conservation of this partially ordered domain (Figure 2). Within the hydrophobic segments are several conserved proline residues that slow aggregation, as demonstrated by recent Pro→Ala mutagenesis studies.²⁸ However, the most significant decrease in lag time observed for these mutants relative to wild type is approximately twofold, and significantly less than the factor of ten reduction in lag time observed for the truncated species here. By examining detailed kinetics and thermodynamic properties from a range of disease associated truncated and phosphorylated species, our studies provide quantitative support for a protective role of the α -syn C-terminus and demonstrate unequivocally the contribution of electrostatics in this inhibitory mechanism. The α -syn C-terminus plays an essential role in monomer stabilization as a result of thermodynamic as well as kinetic factors, and loss of this protective mechanism through truncation may be a critical first step in the development of PD lesions.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank Dr. Vladimir Uversky for helpful comments and Dr. Dale Schenk for generous support. We note that Anthony L. Fink, who initiated this work, passed away on March 3, 2008.

Supported by an NIH grant GM065790 (GLM), a graduate fellowship from Elan Pharmaceuticals (KL), St John's College, Cambridge (TPJK), the Schiff Foundation (SIAC) and the Wellcome and Leverhulme Trusts (CMD).

References

1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. *Nature*. 1997; 388:839–40. [PubMed: 9278044]
2. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. *Annu Rev Biochem*. 2006; 75:333–66. [PubMed: 16756495]
3. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. *J Biol Chem*. 2006; 281:29739–52. [PubMed: 16847063]
4. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jäkälä P, Hartmann T, Price DL, Lee MK. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. *Proc Natl Acad Sci USA*. 2005; 102:2162–7. [PubMed: 15684072]

5. Fujiwara I, Takahashi S, Tadakuma H, Funatsu T, Ishiwata Si. Microscopic analysis of polymerization dynamics with individual actin filaments. *Nat Cell Biol.* 2002; 4:666–73. [PubMed: 12198494]
6. Bisaglia M, Tessari I, Mammi S, Bubacco L. Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. *Neuromolecular Med.* 2009; 11:239–51. [PubMed: 19669606]
7. Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. *Prog Brain Res.* 2010; 183:115–45. [PubMed: 20696318]
8. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. *J Biol Chem.* 1998; 273:9443–9. [PubMed: 9545270]
9. Georgieva ER, Ramlall TF, Borbat PP, Freed JH, Eliezer D. Membrane-bound alpha-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. *J Am Chem Soc.* 2008; 130:12856–7. [PubMed: 18774805]
10. Jao CC, Hegde BG, Chen J, Haworth IS, Langen R. Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. *Proc Natl Acad Sci USA.* 2008; 105:19666–71. [PubMed: 19066219]
11. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. *Proc Natl Acad Sci USA.* 1993; 90:11282–6. [PubMed: 8248242]
12. Der-Sarkissian A, Jao CC, Chen J, Langen R. Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. *J Biol Chem.* 2003; 278:37530–5. [PubMed: 12815044]
13. Hoyer W, Cherny D, Subramaniam V, Jovin TM. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. *Biochemistry.* 2004; 43:16233–42. [PubMed: 15610017]
14. Murray IVJ, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, Trojanowski JQ, Lee VMY. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. *Biochemistry.* 2003; 42:8530–40. [PubMed: 12859200]
15. McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. *J Neuropathol Exp Neurol.* 2009; 68:515–24. [PubMed: 19525899]
16. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT, Fernandez CO, Eliezer D, Zweckstetter M, Lashuel HA. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. *J Biol Chem.* 2008; 283:16895–905. [PubMed: 18343814]
17. DuBay KF, Pawar AP, Chiti F, Zurdo J, Dobson CM, Vendruscolo M. Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. *J Mol Biol.* 2004; 341:1317–26. [PubMed: 15302561]
18. Kaylor J, Bodner N, Edridge S, Yamin G, Hong DP, Fink AL. Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. *J Mol Biol.* 2005; 353:357–72. [PubMed: 16171820]
19. Kheterpal I, Williams A, Murphy C, Bledsoe B, Wetzel R. Structural features of the Abeta amyloid fibril elucidated by limited proteolysis. *Biochemistry.* 2001; 40:11757–67. [PubMed: 11570876]
20. Cribbs DH, Pike CJ, Weinstein SL, Velazquez P, Cotman CW. All-D-enantiomers of beta-amyloid exhibit similar biological properties to all-L-beta-amyloids. *J Biol Chem.* 1997; 272:7431–6. [PubMed: 9054444]
21. Oosawa F, Kasai M. A theory of linear and helical aggregations of macromolecules. *Journal of molecular biology.* 1962; 4:10–21. [PubMed: 14482095]
22. Ferrone FA, Hofrichter J, Eaton WA. Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. *Journal of molecular biology.* 1985; 183:611–31. [PubMed: 4020873]
23. Tanaka M, Weissman JS. An efficient protein transformation protocol for introducing prions into yeast. *Methods in enzymology.* 2006; 412:185–200. [PubMed: 17046659]

24. Knowles TPJ, Waudby CA, Devlin GL, Cohen SIA, Aguzzi A, Vendruscolo M, Terentjev EM, Welland ME, Dobson CM. An analytical solution to the kinetics of breakable filament assembly. *Science*. 2009; 326:1533–7. [PubMed: 20007899]
25. Zhou W, Long C, Reaney SH, Di Monte DA, Fink AL, Uversky VN. Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intramolecular long-range interactions. *Biochim Biophys Acta*. 2010; 1802:322–30. [PubMed: 20026206]
26. Bertonecini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, Jovin TM, Zweckstetter M. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. *Proc Natl Acad Sci USA*. 2005; 102:1430–5. [PubMed: 15671169]
27. Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M, Dobson CM. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. *J Am Chem Soc*. 2005; 127:476–7. [PubMed: 15643843]
28. Meuvius J, Gerard M, Desender L, Baekelandt V, Engelborghs Y. The conformation and the aggregation kinetics of alpha-synuclein depend on the proline residues in its C-terminal region. *Biochemistry*. 2010; 49:9345–52. [PubMed: 20828147]

Figure 1. Dependence of a) lag time and b) extent of aggregation on the C-terminal negative charge (residues 91 – 140, Table 1) of α -syn variants. Experimental details are described in the text and Supplemental Information.

Rat	K	K	D	Q	M	G	K	G	E	E	G	Y	P	Q	E	G	I	L	E	D	M	P	V	D	P	S	S	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Mouse	K	K	D	Q	M	G	K	G	E	E	G	Y	P	Q	E	G	I	L	E	D	M	P	V	D	P	G	S	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Human	K	K	D	Q	L	G	K	N	E	E	G	A	P	Q	E	G	I	L	E	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Chimpanzee	K	K	D	Q	L	G	K	N	E	E	G	A	P	Q	E	G	I	L	E	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Sumatran orangutan	K	K	D	Q	L	G	K	N	E	E	G	A	T	Q	E	G	I	L	E	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Red guenon	K	K	D	Q	L	G	K	N	E	E	G	A	P	Q	E	G	I	L	Q	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Crab-eating macaque	K	K	D	Q	L	G	K	N	E	E	G	A	P	Q	E	G	I	L	Q	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Bonobo	K	K	D	Q	L	G	K	N	E	E	G	A	P	Q	E	G	I	L	E	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Rhesus macaque	K	K	D	Q	L	G	K	N	E	E	G	A	P	Q	E	G	I	L	Q	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Lowland gorilla	K	K	D	Q	L	G	K	N	E	E	G	A	P	Q	E	G	I	L	E	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Pig	K	K	D	Q	L	G	K	N	E	E	G	A	P	Q	E	G	I	L	E	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Cow	K	K	D	H	M	G	K	G	E	E	G	A	S	Q	E	G	I	L	E	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Black-handed spider monkey	K	K	D	H	S	G	K	S	E	E	G	A	P	Q	E	G	I	L	E	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Common woolly monkey	K	K	D	H	S	G	K	S	E	E	G	A	P	Q	E	G	I	L	E	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A
Red-cheated mustached tamarin	R	K	D	H	L	G	K	S	E	E	G	A	P	Q	E	G	I	L	E	D	M	P	V	D	P	D	N	E	A	Y	E	M	P	S	E	E	G	Y	Q	D	Y	E	P	E	A

Figure 2.

Alignment of the α -syn C-terminal region (residues 96-140) showing conservation of the negatively charged residues (red columns). Data were obtained from UnitProtKB.

Figure 3. Relationship between lag time and degree of aggregation at the end of a kinetic trial for truncated and phosphorylated α -syn variants. Best fits to the filament assembly model are shown for variation in the fibril dissociation rate (dashed line) and monomer addition rate (solid line). Full details and additional mechanisms are provided in Supplemental Information.

Table 1 **α -Synuclein Sequences**

WT ^{a,b}	α -syn(1-90)-ATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA
P-syn ^c	α -syn(1-90)-ATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA
D135	α -syn(1-90)-ATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQD
P-D135 ^c	α -syn(1-90)-ATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQD
Y133	α -syn(1-90)-ATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGY
P-Y133 ^c	α -syn(1-90)-ATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGY
N122	α -syn(1-90)-ATGFVKKDQLGKNEEGAPQEGILEDMPVDPDN
D119	α -syn(1-90)-ATGFVKKDQLGKNEEGAPQEGILEDMPVD

^a Sequence details are shown for residues 91 – 140.

^b Acidic residues are red.

^c Phosphorylated Ser is blue.